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Abstract: The terpenoid 17-O-acetylacuminolide (AA) was shown to inhibit the production 
of several inflammatory mediators. However, the mechanisms by which this compound elicited 
its anti-inflammatory activity remain to be elucidated. In this study, we analyzed the effects of 
AA on inflammatory gene expression in two different cell types with primordial importance 
in the inflammatory processes – endothelial cells and macrophages. In human umbilical vein 
endothelial cells, AA inhibited the expression of inflammatory proteins including the adhesion 
molecules intercellular adhesion molecule 1; vascular cell adhesion molecule 1; and E-selectin, 
as well as the release of the chemokine interleukin-8. Additionally, AA hindered the formation 
of capillary-like tubes in an in vitro model of angiogenesis. AA’s effects in endothelial cells can 
be attributed at least in part to AA’s inhibition of tumor necrosis factor alpha-induced nuclear 
factor of kappa light polypeptide gene enhancer in B-cells (NF-κB)’s translocation. Also, in 
lipopolysaccharide-stimulated macrophage-like RAW264.7 cells, AA was able to downregulate 
the expression of the genes cyclooxygenase 2, inducible nitric oxide synthase, interleukin-6, and 
chemokine (C-C motif) ligand 2. Moreover, AA inhibited the phosphorylation of nuclear factor 
of kappa light polypeptide gene enhancer in B-cells inhibitor-alpha (IκBα), IκB kinase (IKK), 
and the mitogen-activated protein kinases JNK, ERK, and p38. In conclusion, the present results 
further support the anti-inflammatory potential of AA in different models of inflammation.
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Introduction
Of particular importance during an inflammatory response is the vascular endothelium. 
By increasing endothelial cells’ permeability, blood vessels are responsible for the 
transportation and dissemination of monocytes and monocyte-derived tissue mac-
rophages, which play an essential role in both acute and chronic inflammation.1 More-
over, activation of the endothelium with stimuli, such as lipopolysaccharide (LPS) and 
cytokines, leads to the expression of chemokines, such as interleukin (IL)-8,2 as well as 
adhesion molecules,3 including intercellular adhesion molecule 1 (ICAM-1), vascular 
cell adhesion molecule 1 (VCAM-1), and E-selectin.4 The expression of these molecules 
plays an important role in adhesion and extravasation of leukocytes in an inflammatory 
response,5,6 as well as in the attachment and metastasis of cancer cells.7
One of the main mediators in inflammatory responses is the transcription factor 
nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF-κB). NF-κB not 
only influences the expression of cytokines and inducible inflammatory enzymes, but 
it also modulates the expression of survival genes, chemokines, adhesion molecules, 
and angiogenesis.8 Under physiological conditions, NF-κB is found in the cytoplasm, 
where it is bound to a protein called the inhibitor of NF-κB (IκBα). The IκBα  inhibits 
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the translocation of NF-κB into the nucleus. However, 
stimulation by a wide range of proinflammatory mediators 
including cytokines (tumor necrosis factor alpha [TNF-α] 
and IL-1) and infections with bacteria or viruses leads to 
NF-κB activation.9 This is achieved via the phosphorylation 
of IκBα by the IκB kinase complex (IKK). The IKK complex 
is composed of the catalytic IKKα and IKKβ subunits and a 
regulatory protein termed IKKγ. This complex is activated via 
cascades of signals depending on the initial stimulus.10 The 
LPS stimulation will activate toll-like receptor 4 signaling, 
leading to IKK complex activation. Once the IKK complex 
phosphorylates IκBα, the latter is eventually degraded by the 
proteasome, and NF-κB is free to translocate to the nucleus, 
where it carries out its transcriptional activities.11
In addition to the NF-κB activation, LPS can also activate 
mitogen-activated protein kinases (MAPKs).12 The MAPKs 
of interest in this study are three subgroups: extracellular 
signal-regulated kinases (ERK1/2); c-jun N-terminal or 
stress-activated protein kinase (JNK); and p38 protein kinase. 
These kinases play key roles in regulating numerous cellular 
functions, including cell growth, apoptosis, and cellular 
responses to inflammation.13 
Several studies explored the various biological activities 
of terpenoids,14 a class of secondary metabolites to which the 
compound 17-O-acetylacuminolide (AA) belongs.15 We have 
recently described the isolation and some anti-inflammatory 
effects of this diterpene labdane.16 The current study looks 
into additional anti-inflammatory effects of this compound, as 
well as possible mechanisms of action involved. We explored 
its effects on the expression of adhesion molecules, cytokines, 
and other NF-κB target genes in TNF-α-stimulated human 
umbilical vein endothelial cells (HUVECs) and the LPS-
induced macrophage cell line RAW264.7.
Additionally, due to the role NF-κB plays in angiogenesis,17,18 
AA’s effect on tube formation was tested. The cytotoxicity of 
this compound was investigated in parallel with the different 
assays to avoid interference of cell death. AA was also tested 
in the human hepatic cell line (WRL-68) as a preliminary 
indicator of compound safety.19,20
Materials and methods
cell lines and reagents
Cell lines RAW264.7 and WRL-68 were obtained from Amer-
ican Type Culture Collection (ATCC), Manassas, VA, USA. 
HUVEC and the endothelial cell growth medium (EGM™-2) 
Bulletkit™ containing basal medium, supplements, and 
growth factors were obtained from Lonza Group Ltd. (Basel, 
Switzerland). Suramin sodium salt (with a purity of 95%), 
curcumin (94%), BAY11-7085 (98%) and human TNF-α 
were obtained from Sigma-Aldrich Co., St Louis, MO, USA. 
The NF-κB translocation and cytoskeletal rearrangement kits 
were from Thermo Fisher Scientific (Waltham, MA, USA). 
For electrophoretic mobility shift assay (EMSA) reagents, 
Poly-deoxy-inosinic-deoxy-cytidylic acid (Poly[d(I-C)]) 
was from Hoffman-La Roche Ltd. (Basel, Switzerland), 
and [α-32P] deoxycytidine 5’-triphosphate (dCTP) was from 
PerkinElmer Inc. (Waltham, MA, USA). 
The Nuclear Extraction Kit was from Cayman Chemical 
Company (Ann Arbor, MI, USA). Monoclonal antibod-
ies for β-actin, phosphorylated NFκB inhibitor (P-IκBα), 
IκBα, mouse immunoglobulin G (IgG), phosphorylated IKK 
(P-IKK)α/β (Ser-176)-R, rabbit IgG, and the peroxidase-
conjugated secondary antibodies goat antimouse IgG–HRP, 
and goat antirabbit IgG-horseradish peroxidase (HRP) were 
from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). 
The Amersham enhanced chemiluminescence (ECL™) 
Western Blotting Detection Reagent was from Amersham 
Biosciences Corp. (GE Healthcare UK Ltd., Little Chalfont, 
UK). The Mitogen-activated protein kinase kinase (MEK), 
MAPK, and p38 inhibitors U0126 (with a purity of 95%), 
PD98059 (95%), SB203580 (98%), ICAM-1, VCAM-1, 
and E-selectin human enzyme-linked immunosorbent assay 
(ELISA) kits were obtained from Thermo Fisher Scientific 
(Waltham, MA, USA). The Human CXCL8/IL-8 Quantikine 
ELISA Kit was obtained from R&D Systems, Inc., (Min-
neapolis, MN, USA). 
The AA (with a purity of 98.5% as determined by high-
performance liquid chromatography) was isolated and purified 
from Neouvaria foetida in our labs, as described previously,16 
and was dissolved in dimethyl sulfoxide (DMSO) and diluted 
in Dulbecco’s Modified Eagle’s Medium or phosphate buff-
ered saline (PBS) before it was used for testing its biological 
activity. BD Matrigel™ Matrix (phenol red-free) was from 
BD Biosciences (San Jose, CA, USA). The RNeasy Mini Kit 
for RNA extraction was from Qiagen GmbH (Hilden, Ger-
many). For the quantitative polymerase chain reaction (PCR) 
analysis, oligo-dT and ribonuclease inhibitor were obtained 
from New England Biolabs (Ipswich, MA, USA). The Molo-
ney murine leukemia virus (MMLV) reverse transcriptase, 
MMLV reverse transcriptase buffer (5×), and deoxyribo-
nucleotides were from Promega  Corporation ( Madison, WI, 
USA), murine primers were from Sigma-Aldrich Co., and 
Thermo Fisher Scientific, and SYBR® Green was from Bio-
Rad Laboratories Inc., Hercules, CA, USA. 
cell culture 
Cell lines were maintained in Dulbecco’s Modified Eagle’s 
Medium with 10% fetal bovine serum (FBS). HUVECs 
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were maintained as recommended in complete endothelial 
growth medium with 2% FBS. The cells were cultured every 
2–3 days using standard aseptic techniques. 
cell viability and cytotoxicity
The viability of the cells was assessed using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) colorimetric assay as described,21 with some 
modifications. WRL-68 cells were seeded at 10,000 cells/
well overnight and were either left untreated (UT) or were 
treated with AA (0.08–50 µg/mL) for either 24 or 72 hours. 
After MTT treatment, the optical density of the samples was 
measured and compared to that of the negative control to 
obtain the percentage viability as follows: 
Cell viability (%) =  [(OD
570
 (sample)/OD
570
  
(negative control)) ×100], (1)
where OD
570
 is the optical density or absorbance at 570 nm.
real-time quantitative Pcr analysis 
of selected murine inflammatory genes: 
cell treatment and rna isolation
For quantitative PCR analysis, the protocol was as previously 
described,22 with some modifications. The RAW264.7 cells 
were seeded overnight at 1×106 cells/well in 6-well plates. The 
cells were then either left UT or were pretreated with the indi-
cated concentrations of AA for 30 minutes. Subsequently, the 
cells were either left with no LPS treatment or were stimulated 
with 1 µg/mL of LPS for either 1 hour (IL-6 and chemokine 
[C-C motif] ligand 2 [CCL-2]) or 4 hours (cyclooxygenase 
2 [COX-2] and inducible nitric oxide synthase [iNOS]). The 
cells were washed with cold PBS, and total cellular RNA was 
isolated using TRIzol® (Thermo Fisher Scientific). The RNA 
quantity and quality were assessed using the NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific), and the RNA 
was stored at -70°C until use. 
reverse transcription
In addition, 500 ng of RNA sample was mixed with 2.5 mM 
of oligo(deoxy-thymine [dT]) and brought to a final 
 volume of 16.5 µL with nuclease-free water per reaction. 
The samples were heated for 5 minutes at 70°C and were 
subsequently cooled on ice. These mixtures were further 
supplemented with MMLV-reverse transcriptase and incu-
bated at 37°C for 1 hour, followed by heating to 70°C for 
10 minutes. The prepared complementary DNA was stored 
at -20°C until analysis. 
real-time quantitative Pcr with sYBr® 
green
SYBR® Green, complementary DNA samples, and forward 
and reverse primers of the gene of interest were used for 
quantitative PCR analyses to detect gene expression of CCL-2, 
IL-6, iNOS, COX-2, and cyclophilin (as a housekeeping gene), 
using the Roche LightCycler® 480 II instrument and LightCy-
cler® 480 (Hoffman-La Roche Ltd.) Software Version 5. The 
protocol used was SYBR® fast-run protocol. The sequences 
of the primers used in this study are listed in Table 1. 
nuclear extraction and eMsa
RAW264.7 macrophages cells were plated in 6-well plates 
(1×106 cells/well). The cells were either pretreated with 
5 µg/mL AA for 30 minutes or with complete medium. 
The cells were then either stimulated with 1 µg/mL LPS 
for 30 minutes, or they were left UT. Nuclear extracts were 
prepared and frozen at -70°C until use.
The EMSA protocol conducted was as previously 
described23 with some minor modifications. Also, 10 µg of the 
nuclear extract proteins were mixed with 12 µL of a mixture 
containing binding buffer, poly-deoxy-inosinic-deoxy-cyti-
dylic acid (Poly[d(I-C)]), bovine serum albumin (BSA), and 
an NFκB-specific 32P-labeled oligonucleotide comprising the 
sequence 5′-AGCTATGTGGGTTTTCCCATGAGC-3′, in 
which the single IL-6 promoter-derived NFκB motif is bold 
and underlined. The mixture was incubated for 15 minutes 
at room temperature and then loaded onto native 6% poly-
acrylamide gel and run in tris(hydroxymethyl)aminomethane 
(Tris) borate-ethylene-diamine-tetraacetic acid buffer (pH 
8). After electrophoresis, the gels were fixed in triacetic 
acid solution for 5 minutes and vacuum-dried for 2 hours at 
Table 1 sequences of the primers used for quantitative Pcr analysis 
Gene Forward sequence Reverse sequence
Cyclophilin 5′gcaTacgggTccTggcaTcTTgTcc-3′ 5′aTggTgaTcTTcTTgcTggTcTTgc-3′
CCL-2 5′-ccagcaccagcaccagccaa-3′ 5′-ggggcgTTaacTgcaTcTggc-3′
IL-6 5′-TcTcTgggaaaTcgTggaaa-3′ 5′-TcagaaTTgccaTTgcacaac-3′
iNOS 5′-ggagcaggTcgaagacTaT-3′ 5′-cTccaaggaagagTgagag-3′
COX-2 5′-TggTgccTggTcTgaTgaTg-3′ 5′-gTggTaaccgcTcaggTgTTg-3′
Abbreviations: Pcr, polymerase chain reaction; ccl-2, chemokine (c-c motif) ligand 2; il, interleukin; inOs, inducible nitric oxide synthase; cOX-2, cyclooxygenase 2.
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70°C and exposed to a Phosphor Imager screen (Amersham 
Biosciences, GE Healthcare UK Ltd.). 
sodium dodecyl sulfate – polyacrylamide 
gel electrophoresis and Western blotting 
RAW264.7 cells were grown to confluence and for MAPK 
analysis were then starved in medium containing 2% 
FBS for 18 hours. Cells were pretreated with either AA 
(1.25–10 µg/mL) or the medium containing the correspond-
ing DMSO concentrations or the MAPK inhibitors U0126, 
PD98059, and SB203580 at 50 µM for 1 hour. The cells were 
then stimulated with 1 µg/mL LPS for 15 minutes or were 
left unstimulated. Also, 20 µg of the cytoplasmic lysates 
were resolved by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and blotted onto nitrocel-
lulose membranes.
The membrane was blocked overnight in a 5% milk 
solution in PBS with 0.05% Tween 20 (PBST) at 4°C. The 
membranes were then washed with PBST and incubated 
with the primary antibodies of interest for 2 hours at room 
temperature. After washing with the blocking buffer, the 
membranes were incubated with the appropriate secondary 
antibodies (1:2,000) for 1 hour. Depending on the secondary 
antibody used, the membranes were either developed using 
the ODYSSEY® CLx Imager (LI-COR, Inc., Lincoln, NE, 
USA) or the Amersham ECL™ Western Blotting Detection 
Reagent, according to the manufacturer’s protocol. The 
infrared-dye fluorescence was detected using the Odyssey 
V3 software (LI-COR, Inc.), while chemifluorescence was 
detected using the BioSpectrum® Imaging System from UVP, 
LLC (Upland, CA, USA). Where necessary, the membranes 
were stripped, blocked, and reprobed with the appropriate 
primary antibodies of the unphosphorylated forms of the 
proteins of interest.
elisa assays
HUVECs were seeded overnight and were then either left UT 
or stimulated with the indicated concentrations of AA in com-
bination with 1 µg/mL of LPS for 4 hours or 5 ng/mL human 
TNF-α overnight. As a positive control, the cells were also 
treated with 10 µM of the positive control BAY 11-7085. 
For all assays, cell supernatant was aspirated and frozen 
at -80°C until analysis, while cell viability was evaluated 
with the MTT assay as described in “Cell viability and cyto-
toxicity”. The IL-8 concentrations were determined using 
the Human IL-8 ELISA kit, and the Human ELISA kits for 
the respective adhesion molecules were used to measure the 
concentrations of released adhesion molecules.
Tube formation assay
Matrigel was thawed overnight at 4°C, and 50 µL of the 
solution was added to a 96-well plate. The gel was allowed 
to polymerize at 37°C for 30 minutes. HUVECs were seeded 
at 20,000 cells/well on either a regular 96-well plate for 
testing viability, or on a clear-bottom black plate coated 
with matrigel. The cells were left UT in medium, or they 
were treated with the positive control suramin (50 µM) or 
indicated concentrations of AA, for 16–18 hours.24,25 Tube 
formation was evaluated using the cytoskeletal rearrangement 
kit from Cellomics (Thermo Fisher Scientific), according 
to the manufacturer’s protocols of fixing and staining. The 
Tube Formation BioApplication (Thermo Fisher Scientific) 
was used to quantify tubes formed. Viability was determined 
using MTT, as described earlier.
nF-κB translocation assay
HUVECs were seeded overnight in a 96-well plate at 
6,000 cells/well. The cells were either pretreated for 1 hour 
with either the positive control curcumin (6.25 µg/mL), the 
different concentrations of AA, or were left UT. The cells 
were stimulated with 2 ng/mL TNF-α for 30 minutes. The 
medium was discarded and cells were fixed and stained 
using Cellomics® NF-κB activation kit from Thermo Fisher 
Scientific, according to the manufacturer’s instructions. The 
assay plate was evaluated on the ArrayScan high content 
screening (HCS) Reader. The Cytoplasm to Nucleus Transloca-
tion Bio-Application software (Thermo Fisher Scientific) was 
used to calculate the ratio of cytoplasmic and nuclear NF-κB 
intensity.26 The ratios were then compared among stimulated, 
treated, and UT cells.
statistical analyses
The assays were conducted in at least three separate experi-
ments, unless otherwise specified. Data are expressed as 
the mean ± standard deviation. Data were analyzed using 
GraphPad Prism® statistical software (version 4; GraphPad 
Software Inc., La Jolla, CA, USA) for one-way analysis of 
variance with Tukey’s post hoc test or Student’s t-test, as 
indicated. Differences were considered significant at P0.05. 
The half maximal inhibitory concentration (IC
50
) was cal-
culated using a sigmoidal dose-response (variable slope) 
equation under nonlinear regression (curve fit) utilizing the 
same software. Where inhibition is calculated, values from 
UT, unstimulated cells were considered as the maximum 
inhibition (100%). Inhibition is calculated as follows: 
% inhibition =100× [([control] - [sample])/[control]]. (2)
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Results
We have previously demonstrated that treating RAW264.7 
cells with AA for 24 hours had no significant effect on their 
viability with concentrations ranging from 0.01–5 µg/mL.16 
For short-duration assays (2 hours) required for the 
evaluation of NF-κB and MAPKs activation, moderately 
high doses were used for which no significant toxicity was 
observed. Except for the highest concentration tested of 
50 µg/mL, AA did not elicit a significant cytotoxic effect 
when tested at doses ranging from 0.08–5 µg/mL after 
24 and 72 hours’ treatment in the human hepatic cell line 
WRL-68 (Figure 1).
Triggering of endothelial cells and macrophages with 
proinflammatory stimuli leads to profound induction of a 
wide range of NF-κB-controlled genes, including adhesion 
molecules, cytokines, chemokines, as well as proinflam-
matory enzymes. The anti-inflammatory effect of AA in 
RAW264.7 cells was analyzed by exploring its effects on 
the LPS-induced transcription of NF-κB regulated genes. 
Treatment of cells with LPS for 1 hour led to a significant 
increase in the expression of the IL-6 gene and the monocyte 
chemotactic protein 1 gene CCL-2; whereas, a significant 
increase in iNOS and COX-2 gene expression was observed 
following 4 hours of LPS stimulation. Additionally, AA at 
concentrations of 1.25 and 2.5 µg/mL significantly inhibited 
the LPS-induced expression of all four genes (Figure 2).
Activation of the transcription factor NF-κB is tightly 
regulated and requires several steps of protein–protein 
interactions and phosphorylation events finally leading 
to the nuclear translocation of NF-κB from the cytoplasm 
to the nucleus. There, NF-κB will bind to its specific rec-
ognition sequences in the promoter of NF-κB-regulated 
genes. We analyzed the effect of AA on DNA binding 
and the nuclear translocation of NF-κB. The EMSA 
analysis indicated enhanced binding to the NF-κB DNA 
consensus sequence in the LPS-treated nuclear extracts of 
RAW264.7 cells compared to UT cells (Figure 3). Pretreat-
ment of cells with vehicle (DMSO) did not affect NF-κB 
DNA binding. On the other hand, pretreatment with AA 
at 5 µg/mL significantly suppressed the NF-κB complex 
band intensity (Figure 3).
Phosphorylation and activation of the IKK complex fol-
lowed by phosphorylation and degradation of IκBα precedes 
the nuclear translocation of NF-κB. We analyzed the effects 
of AA on these events to further determine the mechanism 
of action by which AA inhibited NF-κB translocation. As 
depicted in Figure 4, stimulation with LPS for 15 minutes 
caused the degradation and phosphorylation of the IκBα 
125
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Figure 1 effects of aa on Wrl-68 viability.
Notes: Wrl-68 cells were treated with aa for 24 hours (gray bars) and 72 hours (dotted bars) at indicated concentrations. Viability was measured using MTT assay and 
data are the average of four independent experiments (± sD) and were analyzed using one-way anOVa with Tukey’s post hoc test. ***P0.001. 
Abbreviations: aa, 17-O-acetylacuminolide; sD, standard deviation; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; anOVa, analysis of variance. 
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protein (Figure 4A and B, respectively). Moreover, increased 
phosphorylation of IKKα/β was observed in cells stimulated 
with LPS, and pretreatment with AA was able to significantly 
reduce this effect of LPS (Figure 4C).
Because the MAPKs (p38, JNK, and ERK1/2) play 
essential roles in cell signaling pathways that regulate 
inflammation, the effects of AA on the activation of MAPKs 
were evaluated using Western blotting. The stimulation of 
RAW264.7 cells with LPS for 30 minutes caused prominent 
phosphorylation of all MAPKs as a mark for their activa-
tion, as manifested by the increased band intensity in vehicle 
pretreated and UT cells (0 µg/mL).
However, AA pretreatment (1.25–5 µg/mL) decreased 
LPS-induced MAPKs phosphorylation, as manifested by 
the lower band intensities of the phosphorylated form of the 
MAPKs with no effect on the total expression level of these 
MAPKs (Figures 5 and 6). On the other hand, treatment of 
cells with AA alone at high concentrations caused significant 
phosphorylation of JNK and p38, but it had no effect on ERK 
activation (Figure 7). 
To gain further insight on the anti-inflammatory action 
of AA, we analyzed the TNF-α- or LPS-mediated release 
of adhesion molecules ICAM-1, VCAM-1, and E-selectin, 
as well as the IL-8 in endothelial HUVEC cells by specific 
ELISA. Pretreatment with AA significantly reduced the 
TNF-α-induced expression of these molecules without 
affecting the viability. Regulation of protein expression with 
no effect on cell viability was observed at different concen-
trations of AA: 0.01–0.32 µg/mL for ICAM-1 (Figure 8); 
0.005–1.25 µg/mL for VCAM-1; and 0.01–0.08 µg/mL 
for E-selectin (Figure 9A and B). Moreover, LPS induced 
IL-8 production was significantly inhibited by AA under 
conditions where no effect on cell viability can be detected 
(Figure 10).
Angiogenesis, the formation of new blood vessels from 
existing blood vessels, underlies the pathophysiology of 
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Figure 2 inhibitory effect of aa on lPs-induced expression of indicated genes in raW264.7 cells.
Notes: AA significantly inhibited gene expression of CCL-2 (A), il-6 (B), inOs (C) and cOX-2 (D). cells were seeded overnight and were either left UT or pretreated with 
aa for 30 minutes. cells were then stimulated with lPs or left unstimulated. The rna was extracted, and gene expression was measured using real-time quantitative Pcr. 
Data are the average of two independent experiments; the data were analyzed using one-way anOVa with Tukey’s post hoc test. *P0.05; **P0.01; ***P0.001. 
Abbreviations: aa, 17-O-acetylacuminolide; ccl-2, chemokine (c-c motif) ligand 2; cOX-2, cyclooxygenase 2; lPs, lipopolysaccharide; il, interleukin; Pcr, polymerase 
chain reaction; inOs, inducible nitric oxide synthase; UT, untreated; anOVa, analysis of variance.
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several chronic inflammatory diseases, such as rheuma-
toid arthritis and atherosclerosis. To further elucidate the 
anti-inflammatory capacity of AA, we evaluated its effects 
on the endothelial tube formation, in an in vitro model of 
angiogenesis. HUVECs were grown overnight on matrigel 
to form a capillary-like network of tubes.
Treatment with AA at indicated concentrations sig-
nificantly inhibited tube formation (Figure 11A). While 
high concentrations of 5 µg/mL and 10 µg/mL AA were 
cytotoxic to the cells when tested in a viability assay, the 
lowest concentration tested (2.5 µg/mL) had no effect 
on cell viability and effectively inhibited tube formation 
(Figure 11B and C). Since NF-κB activation is involved 
with both cytokines’ production and angiogenesis, we per-
formed immunofluorescence staining for the NF-κB subunit 
p65. This analysis demonstrated a 1.8-fold increase in ratio 
nucleus:cytoplasm levels of NF-κB in TNF-α-stimulated 
HUVEC cells. AA pretreatment significantly reduced NF-κB 
translocation with an IC
50
 of 2.8 µg/mL (Figure 12).
Discussion 
This study looked into the various immunological effects 
of AA. Due to the fact that this compound was initially 
characterized as a cytotoxic compound,15 it was particularly 
important to look into its effects on cell viability to avoid 
attributing the anti-inflammatory effects to direct cellular 
toxicity. Moreover, by testing the compound in the human 
hepatic cell line,27 WRL-68, preliminary conclusions about 
the safety of the compound may be deduced.19,20 The com-
pound seemed to be relatively safe when tested in WRL-68, 
with no significant toxic effects observed. Additionally, the 
compound’s cytotoxicity was assessed simultaneously with 
the in vitro inflammatory cell models used, and only noncy-
totoxic concentrations were subsequently evaluated. 
Figure 3 effects of aa on nF-κB consensus sequence binding activity.
Notes: raW264.7 cells were seeded overnight and pretreated for 30 minutes with 5 µg/ml aa, the equivalent percentage of vehicle (DMsO) or were left UT in complete 
medium. The cells were then stimulated with 1 µg/ml of lPs as indicated for 30 minutes. nuclear extracts were prepared as described earlier and analyzed with eMsa. 
The protein and Dna complex were detected with Phosphor imager. The image is representative of three independent experiments.
Abbreviations: aa, 17-O-acetylacuminolide; DMsO, dimethyl sulfoxide; UT, untreated; lPs, lipopolysaccharide; nFκB, nuclear factor kappa-light-chain-enhancer of 
activated B-cells; rBPJκ, recombination signal binding protein for immunoglobulin kappa J region; eMsa, electrophoretic mobility shift assay.
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In addition to the expression of cytokines and induc-
ible inflammatory enzymes, the transcription factor NF-κB 
modulates the expression of survival genes, chemokines, and 
adhesion molecules.8 Therefore, NF-κB plays an important 
role in several processes including inflammation, angiogen-
esis, and carcinogenesis.28 We have previously demonstrated 
that AA inhibited the production of several inflammatory 
cytokines, both in vitro and in vivo.16 
Looking into the additional anti-inflammatory effects of 
AA revealed its ability to inhibit IL-6 messenger ribonucleic 
acid, which was significantly induced upon LPS stimulation 
in macrophage-like RAW264.7 cells. The same was true 
for the messenger ribonucleic acid of the inflammatory 
chemokine monocyte chemotactic protein 1, CCL-2. In addi-
tion to downregulating several inflammatory cytokines, AA 
dose-dependently inhibited the transcription of the inducible 
inflammatory enzymes iNOS and COX-2, both of which play 
important roles in inflammation and are targets of several 
anti-inflammatory drugs.29,30
Due to the fact that the expression of COX-2, iNOS,31 
and proinflammatory cytokines and mediators32 is regu-
lated, at least in part, by the transcription factor NF-κB, 
the role AA plays in inhibiting the translocation of NF-κB 
and its DNA-binding were explored. The EMSA analysis 
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Figure 4 effects of aa on iκBα degradation and the phosphorylation of iκBα and iKKα/β in lPs-stimulated raW264.7 cells.
Notes: Cells were grown to confluence and were either left UT (control), or pretreated with curcumin at 6.25 µg/ml or aa at 5 µg/ml for 30 minutes. The cells were then 
stimulated with 1 µg/ml of lPs for 15 minutes for iκBα degradation and phosphorylation, (A & B) respectively. For the analysis of iKK phosphorylation (C), the cells were 
stimulated with 1 µg/ml of lPs for 5 minutes. The effects on the proteins of interest were detected by Western blotting. The data are an average of two independent experiments 
and were analyzed using one-way ANOVA. Means were compared to LPS-treated cells (LPS) and indicated when significantly different. *P0.05; **P0.01; ***P0.001.
Abbreviations: aa, 17-O-acetylacuminolide; avg, average; iκB, nuclear factor of kappa light polypeptide gene enhancer; iκBα, nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor-alpha; iKKα/β, iκB kinase alpha/beta; lPs, lipopolysaccharide; anOVa, analysis of variance; P, phosphorylated; UT, untreated.
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confirmed the inhibition of NF-κB activation as the com-
pound inhibited binding of NF-κB to its DNA recognition 
sequence. The inhibition of NF-κB/DNA binding indicates 
either no or little NF-κB translocation to the nucleus, or an 
impaired binding of NF-κB to its binding site on the DNA 
sequence, both of which would inhibit NF-κB-mediated 
transcriptional activity. To delineate the mechanism of action 
by which AA inhibited the NF-κB activation, the effects of 
the compound on upstream kinases were explored. The AA 
significantly inhibited the LPS-induced phosphorylation 
and degradation of IκBα, hence sequestering NF-κB in the 
cytoplasm.33 The mechanism of action was further elucidated 
by revealing the inhibitory effect of AA on LPS-induced 
IKKα/β phosphorylation, which is required for IκBα phos-
phorylation, and ultimately NF-κB activation.34 Cysteine 179 
(Cys179) of the enzyme IKKβ plays a critical role in enzyme 
activation by promoting the phosphorylation of activation-
loop serines (Ser-177 and Ser-181).35 Cys179 in the activation 
loop of IKKβ is known to be the target site for IKK inhibitors, 
including several terpenoids.36–38 It was shown previously that 
the Michael acceptor groups, such as that present in AA, can 
attack critical cysteines in target proteins.14 This presents a 
possible mechanism by which AA inhibits the IKK complex 
and exerts its anti-inflammatory effects. 
In addition to NF-κB activation, LPS stimulation was 
also shown to activate MAPKs.39 MAPKs are involved in the 
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Figure 5 effects of different doses of aa pretreatment on lPs-induced MaPKs phosphorylation.
Notes: RAW264.7 cells were grown to confluence and were starved in medium containing 2% FBS for 18 hours. The cells were then either left UT in medium or were 
pretreated with indicated concentrations of aa or equivalent dimethyl sulfoxide concentrations or the indicated MaPK inhibitors for 1 hour. The cells were then stimulated 
with 1 µg/ml lPs for 15 minutes or were left unstimulated. Proteins were extracted and detected by Western blotting, and images are representative of at least three 
independent experiments. When compared to the lPs-stimulated cells (0 µg/ml aa) and UT cells (0); aa-pretreated cells decreased all MaPKs phosphorylation at all 
concentrations for P-erK (A) and at concentrations ranging from 1.25–5 µg/ml for P-JnK and P-p38 (B and C, respectively) in the presence of lPs stimulation for 15 minutes. 
On the other hand, pretreatment with 10 µg/ml of aa increased P-JnK phosphorylation, (B) but not significantly for P-p38 (C).
Abbreviations: aa, 17-O-acetylacuminolide; erK, extracellular signal-regulated kinase; FBs, fetal bovine serum; JnK, c-jun n terminal kinase; lPs, lipopolysaccharide; 
MaPK, mitogen-activated protein kinase; P-erK, phosphorylated erK; P-JnK, phosphorylated JnK, P-p38, phosphorylated p38; UT, untreated.
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inflammatory response mainly by mediating gene expression 
and are, in fact, involved in regulating the activity of NF-κB40 
and activator protein 1 (AP-1).41 
In this study, protein analysis indicated for all three 
MAPKs that their activation by LPS can be inhibited by AA 
at concentrations of 1.25–5 µg/mL. However, although low 
concentrations of AA inhibited LPS-induced MAPK (JNK, 
p38, and ERK1/2) activation, higher doses of AA either alone 
or in combination with LPS seemed to activate JNK and p38 
kinases. This may be due to the fact that the treatment with 
the compound is perceived as a cellular stress signal that can 
activate MAPKs. 
Previously, the activation of JNK and p38 was shown to 
have an inhibitory effect on ERK.42 Indeed, ERK1/2 was not 
activated by AA – even at high doses. The rapid and transient 
activation of MAPKs in response to most stimuli indicate 
that MAPKs function as a biological switch that must be 
downregulated, a task that is carried out by dual specificity 
phosphatases (DUSPs).43 In fact, preliminary microarray 
analysis revealed that the AA pretreatment significantly 
downregulated the expression of DUSP2 and DUSP5 when 
compared to the LPS-treated cells (data not shown). It is 
A
P-
ER
K
:E
R
K
 ra
tio
B
P-
JN
K
:J
N
K
 ra
tio
C
P-
P3
8:
P3
8 
ra
tio
AA (µg/mL)
1.00
*
*
**
**
**
**
***
***
***
***
**
*
*
*
*
*
***
0.75
0.50
0.25
0.00
1.5
1.0
0.5
0.0
0
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.25 2.5 5 10 PD98095 0 1.25 2.5 5 10 U0126
0 1.25 2.5 5 10 SB203580
LPS (1 µg/mL)
AA (µg/mL)
LPS (1 µg/mL)
AA (µg/mL)
LPS (1 µg/mL)
Figure 6 Quantified effects of different AA concentrations on LPS-induced MAPKs phosphorylation in RAW264.7 cells. 
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stimulation for 15 minutes. On the other hand, pretreatment with 10 µg/mL of AA significantly increased P-JNK phosphorylation, (B) but not significantly for P-p38 (C). Data 
are the average of two to three independent experiments and were analyzed with one-way anOVa and Tukey’s post hoc test. *P0.05; **P0.01; ***P0.001.
Abbreviations: aa, 17-O-acetylacuminolide; anOVa, analysis of variance; lPs, lipopolysaccharide; MaPK, mitogen-activated protein kinase; P-erK, phosphorylated 
extracellular signal-regulated kinase; P-JnK, phosphorylated JnK, P-p38, phosphorylated p38; UT, untreated.
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treated with 5 µg/ml and 10 µg/ml of aa for 1 hour. cell lysates were separated on 
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Figure 8 effects of aa on hUVec viability and soluble icaM-1 inhibition.
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inhibition, means were compared to TnF-α-only treated cells and indicated when significantly different. **P0.01; ***P0.001. For cell viability, means were compared to 
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Abbreviations: aa, 17-O-acetylacuminolide; BaY, BaY-117085; hUVec, human umbilical vein endothelial cell; icaM-1, intercellular adhesion molecule 1; TnF-α, tumor 
necrosis factor alpha; elisa, enzyme-linked immunosorbent assay; anOVa, analysis of variance; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; UT, 
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Figure 9 effects of aa on hUVec viability, soluble VcaM-1, and e-selectin secretion.
Notes: hUVecs were seeded at 6,000 cells/well overnight. The cells were left UT or pretreated with either 10 µM of BaY11-7085 or with indicated doses of aa, for 
30 minutes. The cells were then either left UT or stimulated with 5 ng/ml of TnF-α for 16 hours. cell supernatants were collected, and VcaM-1 and e-selectin concentrations 
were evaluated using elisa, while cell viability was determined using MTT. Data are average of two or four experiments for VcaM-1 and e-selectin, respectively. Data were 
analyzed using one-way anOVa, with Tukey’s post hoc test. For inhibition assays in both (A) and (B), means were compared to TnF-α-only treated cells (0 µg/ml) and 
indicated when significantly different (**P0.01; ***P0.001). For cell viability, there was no significant difference when compared to UT cells.
Abbreviations: aa, 17-O-acetylacuminolide; hUVec, human umbilical vein endothelial cell; VcaM-1, vascular cell adhesion molecule 1; UT, untreated; TnF-α, tumor 
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2-yl)-2,5-diphenyltetrazolium bromide. 
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Figure 11 effects of aa on in vitro angiogenesis.
Notes: hUVecs were seeded at 20,000 cells/well. The cells were left in medium (UT), were treated with 50 µM suramin or with indicated doses of aa, for 16–18 hours. 
(A) Fluorescent micrographs of hUVec tube formation and the inhibitory effects of aa; UT (medium) cells grown on matrigel for 16 hours form web-like networks of tubes. 
cells treated with suramin and with aa disrupted this arrangement in a dose-dependent manner. (B) Viability was determined using MTT, and quantified tube formation was 
evaluated using the cytoskeletal rearrangement kit from cellomics (C). Data are average of three experiments and were analyzed using one-way anOVa, with Tukey’s post 
hoc test. Means were significantly different when compared to the UT group, where **P0.01 and ***P0.001. 
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thus possible that the AA’s inhibition of the MAPKs in the 
presence of LPS is due to the combined effects of these 
stressors that bring about the negative regulation of MAPKs 
by DUSPs. Crosstalk between the different MAPKs further 
complicates the ability to specify the point at which they are 
inhibited or activated.42
This study further demonstrates the ability of AA to 
inhibit the expression of the adhesion molecules ICAM-1, 
VCAM-1, and E-selectin as well as the chemokine IL-8 in 
HUVECs at the protein level. In addition to the role of adhe-
sion molecules in inflammation, these proteins play a part in 
tumor metastasis and invasion by facilitating the attachment 
and migration of cancer cells. Since tumor metastasis is a 
multistep process, these provide pharmacological targets for 
anticancer agents. One of these steps is angiogenesis.44 In this 
study, preliminary testing for the inhibition of angiogenesis 
revealed AA’s ability to inhibit tube formation, albeit with 
a narrow window of activity. This is because tube formation 
inhibition at higher concentrations (5–10 µg/mL) was likely 
due to cytotoxicity (Figure 11C).
Recently, we showed that AA inhibited the translocation 
of NF-κB in LPS-treated RAW264.7 cells and TNF-α-treated 
L929 cells.16 In this study, we further confirmed that AA inhib-
ited the nuclear translocation of NF-κB in HUVEC cells, which 
would explain the compound’s ability to reduce the expression 
of the tested adhesion molecules and tube formation.
Taken together, the present study described the anti-
inflammatory and possible anticancer activities of AA in 
several assays. The mechanism of action of AA includes 
the inhibition of several inflammatory kinases, such as the 
enzyme complex IKKα/β and the MAPKs. This confirms 
the compound’s capacity for the development of an anti-
inflammatory and/or anticancer agent by testing it in relevant 
in vivo models of disease. 
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Figure 12 inhibitory effect of aa on the increase of nuclear nF-κB intensity in TnF-α-stimulated hUVecs.
Notes: (A) Micrographs of hUVecs depicting the effects of indicated treatments on nF-κB translocation. (B) Quantification of percentage inhibition of NF-κB translocation; 
hUVecs were pretreated with either 6.25 µg/ml curcumin or the indicated doses of aa for 30 minutes or were left UT. The cells were then stimulated with TnF-α 
(2 ng/ml) for 30 minutes to cause nF-κB translocation to the nucleus or were left UT. Data are the average of two independent experiments (± sD), and were analyzed using 
one-way ANOVA with Tukey’s post hoc test. The effect was significant when groups were compared to TNF-α-treated hUVecs (0 µg/ml). **P0.01; ***P0.001.
Abbreviations: aa, 17-O-acetylacuminolide; nF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; TnF-α, tumor necrosis factor alpha; trans, translocation; 
hUVec, human umbilical vein endothelial cell; sD, standard deviation; anOVa, analysis of variance; UT, untreated.
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